LIFELINE SPAC I OYJ A EO1 (0CD) - Net Assets
Based on the latest financial reports, LIFELINE SPAC I OYJ A EO1 (0CD) has net assets worth €108.00 Million EUR (≈ $126.26 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€117.90 Million ≈ $137.84 Million USD) and total liabilities (€9.90 Million ≈ $11.57 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 0CD cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €108.00 Million |
| % of Total Assets | 91.6% |
| Annual Growth Rate | 128.96% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 1847.98 |
LIFELINE SPAC I OYJ A EO1 - Net Assets Trend (2021–2025)
This chart illustrates how LIFELINE SPAC I OYJ A EO1's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of LIFELINE SPAC I OYJ A EO1 for the complete picture of this company's asset base.
Annual Net Assets for LIFELINE SPAC I OYJ A EO1 (2021–2025)
The table below shows the annual net assets of LIFELINE SPAC I OYJ A EO1 from 2021 to 2025. For live valuation and market cap data, see LIFELINE SPAC I OYJ A EO1 stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €108.00 Million ≈ $126.26 Million |
-4.85% |
| 2024-12-31 | €113.50 Million ≈ $132.69 Million |
+9.56% |
| 2023-12-31 | €103.60 Million ≈ $121.12 Million |
+4255.93% |
| 2022-12-31 | €2.38 Million ≈ $2.78 Million |
-39.48% |
| 2021-12-31 | €3.93 Million ≈ $4.59 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to LIFELINE SPAC I OYJ A EO1's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1356536312.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €122.00 Million | 112.96% |
| Total Equity | €108.00 Million | 100.00% |
LIFELINE SPAC I OYJ A EO1 Competitors by Market Cap
The table below lists competitors of LIFELINE SPAC I OYJ A EO1 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Titomic Ltd
AU:TTT
|
$261.38 Million |
|
Mountain Lake Acquisition Corp. II Class A Ordinary Shares
NASDAQ:MLAA
|
$261.39 Million |
|
Eaton Vance National Municipal Opportunities Closed Fund
NYSE:EOT
|
$261.40 Million |
|
SAB Biotherapeutics Inc
NASDAQ:SABS
|
$261.43 Million |
|
Master Tec Group Berhad
KLSE:0295
|
$261.21 Million |
|
Biostar Microtech International Corp
TW:2399
|
$261.20 Million |
|
Grupa Azoty Zaklady Chemiczne Police SA
WAR:PCE
|
$261.10 Million |
|
TQM CORPORATION
BK:TQM-R
|
$260.95 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in LIFELINE SPAC I OYJ A EO1's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 113,600,000 to 108,000,000, a change of -5,600,000 (-4.9%).
- Net loss of 9,700,000 reduced equity.
- New share issuances of 4,100,000 increased equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-9.70 Million | -8.98% |
| Share Issuances | €4.10 Million | +3.8% |
| Total Change | €- | -4.93% |
Book Value vs Market Value Analysis
This analysis compares LIFELINE SPAC I OYJ A EO1's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.47x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 20.13x to 2.47x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €0.39 | €7.91 | x |
| 2022-12-31 | €0.24 | €7.91 | x |
| 2023-12-31 | €10.36 | €7.91 | x |
| 2024-12-31 | €3.41 | €7.91 | x |
| 2025-12-31 | €3.20 | €7.91 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently LIFELINE SPAC I OYJ A EO1 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -8.98%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -62.18%
- • Asset Turnover: 0.13x
- • Equity Multiplier: 1.09x
- Recent ROE (-8.98%) is above the historical average (-18.86%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -65.24% | 0.00% | 0.00x | 42.76x | €-1.79 Million |
| 2023 | 1.93% | 0.00% | 0.00x | 1.00x | €-8.36 Million |
| 2024 | -3.17% | -109.09% | 0.03x | 1.10x | €-14.96 Million |
| 2025 | -8.98% | -62.18% | 0.13x | 1.09x | €-20.50 Million |
Industry Comparison
This section compares LIFELINE SPAC I OYJ A EO1's net assets metrics with peer companies in the Specialty Chemicals industry.
Industry Context
- Industry: Specialty Chemicals
- Average net assets among peers: $968,609,186
- Average return on equity (ROE) among peers: -119.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| LIFELINE SPAC I OYJ A EO1 (0CD) | €108.00 Million | -65.24% | 0.09x | $261.36 Million |
| GRAPHENE MANUFACT.GROUP (0GF) | $10.10 Million | -116.54% | 0.65x | $185.36 Million |
| Orion Engineered Carbons SA (0OE) | $181.01 Million | 10.03% | 6.68x | $327.05 Million |
| COVESTRO AG SP.ADR 1/2 (1CO1) | $7.76 Billion | 20.82% | 1.01x | $11.11 Billion |
| H&R GmbH & Co. KGaA (2HRA) | $181.68 Million | 13.79% | 1.54x | $183.88 Million |
| LOOP INDUSTRIES DL-001 (3L9) | $14.14 Million | -149.11% | 0.45x | $58.01 Million |
| Dotz Nano Ltd (57N) | $1.04 Million | -784.25% | 0.91x | $4.51 Million |
| TIDEWATER RENEWABLES LTD (7GZ) | $513.13 Million | -7.99% | 1.12x | $233.52 Million |
| DIRECTA PLUS PLC LS-0025 (88K) | $16.03 Million | -22.78% | 0.36x | $2.35 Million |
| TEKNA HOLDING ASA NK 2 (8VB) | $38.35 Million | -37.60% | 0.99x | $67.10 Million |
About LIFELINE SPAC I OYJ A EO1
Canatu Oyj develops and sells carbon nanotubes (CNTs) and related products, and manufacturing equipment for the semiconductor, automotive, and medical diagnostics industries in Finland, the United States, Japan, and Taiwan. The company offers custom CNT synthesis reactors; CNT membrane for high-power EUV lithography and X-Ray filter applications; EUV pellicies to protect photomask for contaminati… Read more